Cargando…

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study

The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-arm multicenter phase 2 design. Eighty-five stage I–II FL pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herfarth, Klaus, Borchmann, Peter, Schnaidt, Sven, Hohloch, Karin, Budach, Volker, Engelhard, Marianne, Viardot, Andreas, Engenhart-Cabillic, Rita, Keller, Ulrich, Reinartz, Gabriele, Eich, Hans-Theodor, Witzens-Harig, Mathias, Hess, Clemens F., Dörken, Bernd, Dürig, Jan, Wiegel, Thomas, Hiddemann, Wolfgang, Hoster, Eva, Pott, Christiane, Dreyling, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745956/ https://www.ncbi.nlm.nih.gov/pubmed/31723798 http://dx.doi.org/10.1097/HS9.0000000000000160

Ejemplares similares

Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
por: König, Laila, et al.
Publicado: (2019)

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma
por: König, Laila, et al.
Publicado: (2020)

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2011)

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2013)

Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial
por: Oertel, Michael, et al.
Publicado: (2023)

Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas
por: Horn, Heike, et al.
Publicado: (2022)

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2021)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
por: Braulke, Friederike, et al.
Publicado: (2022)

P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
por: Oertel, Michael, et al.
Publicado: (2022)

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022)

P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
por: Oertel, Michael, et al.
Publicado: (2022)

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
por: Oertel, Michael, et al.
Publicado: (2022)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
por: Hess, Georg, et al.
Publicado: (2020)

Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic: Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance
por: Oertel, M., et al.
Publicado: (2020)

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2016)

Students’ learning behavior in digital education for radiation oncology
por: Vorwerk, Hilke, et al.
Publicado: (2021)

The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists
por: Oertel, Michael, et al.
Publicado: (2023)

Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized Trials
por: Vidal, Liat, et al.
Publicado: (2018)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Efficacy and Tolerance of IMRT Boost Compared to IORT Boost in Early Breast Cancer: A German Monocenter Study
por: Schumacher, Luisa, et al.
Publicado: (2022)

Dosimetric robustness against setup errors in charged particle radiotherapy of skull base tumors
por: Ammazzalorso, Filippo, et al.
Publicado: (2014)

A phantom based evaluation of the dose prediction and effects in treatment plans, when calculating on a direct density CT reconstruction
por: Flatten, Veronika, et al.
Publicado: (2020)

The fast calibration model for dosimetry with an electronic portal imaging device
por: Schade, Stephanie, et al.
Publicado: (2022)

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017)

Making the right software choice for clinically used equipment in radiation oncology
por: Vorwerk, Hilke, et al.
Publicado: (2014)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma
por: Rolf, Daniel, et al.
Publicado: (2022)

Siah1 proteins enhance radiosensitivity of human breast cancer cells
por: He, Hai-Tao, et al.
Publicado: (2010)

Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
por: Santiago, Alina, et al.
Publicado: (2016)

Changes of lung parenchyma density following high dose radiation therapy for thoracic carcinomas – an automated analysis of follow up CT scans
por: Schröder, Christina, et al.
Publicado: (2019)

Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
por: Enqvist, Monika, et al.
Publicado: (2019)

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
por: Hirt, Carsten, et al.
Publicado: (2021)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
por: Lehners, Nicola, et al.
Publicado: (2017)

Dosimetric impact of reduced nozzle-to-isocenter distance in intensity-modulated proton therapy of intracranial tumors in combined proton-carbon fixed-nozzle treatment facilities
por: Jelen, Urszula, et al.
Publicado: (2013)

Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy
por: Dumke, R., et al.
Publicado: (2022)

Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations: An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO)
por: Dapper, H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8r1p17oobd4q9f43fnnrih4tl7